ACCUPRIL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Accupril, and when can generic versions of Accupril launch?
Accupril is a drug marketed by Pfizer Pharms and is included in one NDA.
The generic ingredient in ACCUPRIL is quinapril hydrochloride. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the quinapril hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Accupril
A generic version of ACCUPRIL was approved as quinapril hydrochloride by CHARTWELL RX on March 2nd, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ACCUPRIL?
- What are the global sales for ACCUPRIL?
- What is Average Wholesale Price for ACCUPRIL?
Summary for ACCUPRIL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 85 |
| Clinical Trials: | 6 |
| Patent Applications: | 3,067 |
| Drug Prices: | Drug price information for ACCUPRIL |
| What excipients (inactive ingredients) are in ACCUPRIL? | ACCUPRIL excipients list |
| DailyMed Link: | ACCUPRIL at DailyMed |
Recent Clinical Trials for ACCUPRIL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Nebraska | Phase 4 |
| Nova Scotia Health Authority | Phase 4 |
| Nova Scotia Health Research Foundation | Phase 4 |
Pharmacology for ACCUPRIL
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
US Patents and Regulatory Information for ACCUPRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-001 | Nov 19, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-004 | Nov 19, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-002 | Nov 19, 1991 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ACCUPRIL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-004 | Nov 19, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-004 | Nov 19, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer Pharms | ACCUPRIL | quinapril hydrochloride | TABLET;ORAL | 019885-003 | Nov 19, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ACCUPRIL
See the table below for patents covering ACCUPRIL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1341330 | DERIVES ACYL SUBSTITUE D'ACIDES 1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXYLIQUES (SUBSTITUTED ACYL DERTIVATIVES OF 1,2,3,4-TETRAHYDROISQUINOLINE-3-CARBOXYLIC ACIDS) | ⤷ Sign Up |
| South Africa | 8800382 | ⤷ Sign Up | |
| Luxembourg | 88321 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ACCUPRIL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0096157 | SPC/GB95/011 | United Kingdom | ⤷ Sign Up | SPC/GB95/011:, EXPIRES: 20060930 |
| 0049605 | SPC/GB93/099 | United Kingdom | ⤷ Sign Up | SPC/GB93/099, EXPIRES: 20040413 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
